

## Subject Index to Volume 10 (1993)

- 1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione, 1206  
2-hydroxypropyl- $\beta$ -cyclodextrin, 156, 1136  
2-pyridone-based human immunodeficiency virus, HPLC, 56  
2'-3'-dideoxyinosine, absorption, 763  
3-acyl-5-FU, 905  
3-hydroxy-3-methylglutaryl-coenzyme A, reductase inhibitor, 1683  
5-fluorouracil (5FU), 905  
 $^{17}$ O nuclear magnetic resonance,  $\beta$ -galactosidase, 103  
 $\alpha$ -chymotrypsin, 1638  
 $\alpha$ -chymotrypsin, degradation, 243  
absorption enhancer, 857  
absorption enhancer, PCC, 1516  
absorption limitation, 743  
absorption, dose, 264  
acacia-gelatin-microencapsulated liposomes, 141  
acetylsalicylic acid release, 141  
acidic fibroblast growth factor, 649, 975  
acitretin, skin permeation, 1291  
acrolein, determination, 1587  
acrylate-methacrylate, 220  
actisomide pharmacokinetics, 427  
activity assay, HIV protease inhibitor, 562  
adriamycin, 895  
aerosol, drug delivery, 1604  
aerosol, lung deposition, 1  
affinity chromatography, 771  
AIDS chemotherapy, 1076, 1136  
albumin microparticles, 1385  
albumin microspheres, drug delivery, 1059  
albuterol, metered dose inhaler, 1381  
alcohol sulfotransferase, 627  
aldose reductase inhibitor, pharmacokinetics, 593  
alendronate, 470  
aluminum and magnesium antacids, 1005  
aluminum hydroxide dissolution, 1458  
alveolar epithelial monolayer, 1668  
alveolar epithelium, transport, 1662  
amino analogues of etoposide, 214  
aminoglycoside nephrotoxicity, 573  
ammonium glycyrrhizinate, 1301  
amylodextrin, complexation, 1280  
amylodextrin, dispersion, 1280  
anesthetic, 884  
anti-HIV compound, 1611  
anti-HIV drugs, 1076  
antifungals, racemic compounds, 136  
antifungals, topical activity, 136  
antineukemic activity, 515  
antimalarial activity, 662  
antiplatelet drug, 777  
antisense peptide, 660  
antitumor agents, 214  
antiviral drugs, 771  
antiviral nucleosides, 1411  
aqueous film coating, 1213, 1363  
arteether, decomposition, 662  
aspartame, demethylation kinetics, 1174  
aspartate degradation, 95  
aspirin hydrolysis, 156  
association polymer, 1144  
asymmetric phospholipids, 147  
azidothymidine, 1338  
 $\beta$ -galactosidase, aggregates, 687  
 $\beta$ -galactosidase, stability in solution, 1484  
 $\beta$ -galactosidase, stability, 103  
 $\beta$ -naphthoflavone, antipyrene interaction, 35  
 $\beta$ -naphthoflavone, time dependent clearance, 35  
batracylin analogues, 918  
bidisomide, absorption sites, 1675  
bilayer permeability, 1654  
bilirubin conjugation, 461  
bioadhesive plant lectins, binding, 1796  
bioadhesive plant lectins, transport, 1796  
bioavailability, 1806  
biodegradable microparticles, 362  
biodegradable microspheres, 391  
bioequivalence, 1806  
bioerodible, drug implants, 369  
biotechnology, recent advances, 1697  
biotin uptake, transport, 282  
biophosphonate, nasal delivery, 924  
blood-brain barrier, tacrine, 44  
bone graft substitutes, 1393  
bone regeneration, 1393  
bromopheniramine enantiomers, 1097  
bronchodilation, isoproterenol, 119  
buccal bioadhesive, 853  
buccal delivery, diclofenac sodium, 126  
bupivacaine, controlled release, 1527  
  
Ca<sup>2+</sup> antagonist, 1346  
Caco-2, cytoprotection, 1620  
calcium pectinate, 258  
camptothecin, pharmacokinetics, 1451  
cancer vaccine, 1715  
capillary electrophoresis, peptides, proteins, 171  
capillary electrophoresis, pharmaceutical analysis, 171  
capillary permeability, 300  
capillary ultrafiltration, 598  
carbamazepine metabolism, 1090  
carbon 13 cross-polarization magic angle spinning spectroscopy, 75  
carbon dioxide atomization, 1385  
carbopol, 1285  
carboxyfluorescein, leakage, 147  
carboxylesterases, 639  
carboxymethyl-dextran, 1253  
carteolol ophthalmic delivery, 386  
cefoxitin, enhanced bioavailability, 1516  
cephadrine, 400  
chelates, 204  
chilled dehydration, gelatin microparticles, 621  
chlorhexidine digluconate, impurities, identification, 1777  
chlorpropamide, polymorphism, 1772  
CI-966 HCL, 1442  
CI-981, 1461  
cisplatin, 1332  
clofazimine analogues, 631  
coating solution penetration, 1363  
codried antacids, 1005  
colon specific drug delivery, 258, 1553  
compactibility, granules, 88  
compaction simulator, 816  
computer-aided drug design, 475  
congestive heart failure, 1341  
conical screening mill, 1248  
controlled release, poly(lactic/glycolic acid), 945  
cryoprotectants, 1232  
crystal growth, metered dose inhalers, 454

- crystal morphology, 1008  
 cytoprotective agents, 1620
- dementia, treatments, 1697  
 dermal absorption, 497  
 desmopressin (dDAVP), 68  
 dexamethasone- $\beta$ -D-glucuronide, 1553  
 dextrans, linear, 1274  
 dextrans, structural characterization, 1274  
 dialysis membrane method, 927  
 diamorphine, 583  
 dibucaine, controlled release, 1527  
 diclofenac sodium, buccal delivery, 126  
 diclofenac, 1688  
 didanosine, 763  
 didanosine, bioavailability, 1157  
 diffusion coefficient, (FT-IR), 616  
 dihydronicotinate N-substitution, 1356  
 dihydroxymethylxanthones, 1187  
 diltiazem, metabolism, 1165  
 diltiazem, pharmacokinetics, 1165  
 diltiazem, sustained release, 757  
 dimethyl- $\beta$ -cyclodextrin, 682  
 dipeptide transport, 667, 1668  
 disposition studies, 335  
*dl-threo*-methylphenidate, enantioselective, 14  
*dl-threo*-methylphenidate, pharmacokinetics, 14  
 DNA topoisomerase II, 214, 343  
 dodecyl 2-(N,N-dimethylamino)propionate, 1632  
 dose proportionality, 289  
 doxorubicin, liposome, 703  
 doxorubicin, pharmacokinetics, 703  
 drug absorption, 843  
 drug delivery, colon, 722  
 drug delivery systems, polymeric micelles, 970  
 drug delivery, albumin microspheres, 1059  
 drug delivery, microemulsion, 1153  
 drug delivery, programmable, 1144  
 drug design, 475  
 drug discovery/development, 889  
 drug implants, 828  
 drug implants, subcutaneous, 369  
 drug release mechanism, 356  
 drug targeting, low molecular weight proteins, 963  
 duodenal pH, elderly, 187
- $\epsilon$ -aminocaproic esters, transdermal penetration, 1015  
 elastase, stabilization, 1478  
 electroosmosis, 1315  
 electrophoresis, 457  
 electrotransport, 1699  
 emulsifiable glass, 1071  
 enkephalins, 1662  
 enteric coated pellets, drug release, 233  
 epithelial permeability, 674  
*Escherichia coli*, 975  
 ethylcellulose, 525  
 etodolac capsules, dissolution, 1295  
 etodolac, bioavailability, 1295  
 etoposide, 343  
 exposure assessment, dermal absorption, 497
- Fab fragment, radioimmunoassay, 69  
 Fab pharmacokinetics, 692  
 fadrozole hydrochloride, linear pharmacokinetics, 1760  
 fadrozole hydrochloride, population characteristics, 1760  
 felodipine extended-release tablet, 709  
 felodipine, gastrointestinal transit, 709  
 field-flow fractionation, 535  
 FK506, HPLC, 1785  
 FK506, oral absorption, 1446  
 floating controlled release, 1321  
 flow-through system, 1521  
 fluid-bed coating, 525
- fluorescence detection, 328  
 fluorescence quenching, 204  
 follicular targeting, 1738  
 formycin B, 611  
 fosinopril sodium, 800  
 Friend retrovirus, 1427
- GABA uptake inhibitor, 1442  
 gabapentin, intestinal absorption, 276  
 gallium, 1130  
 gastric pH, elderly, 187  
 gastric retention, 1087  
 gastrocolonic response, 722  
 gastrointestinal kinetics, 1615  
 gelatin acacia microcapsules, 1115  
 gelatin microparticles, chilled dehydration, 621  
 glucose monitoring, noninvasive, 1751  
 glycosylated dextran, drug targeting, 1253  
 glycosylated dextran, pharmacokinetics, 1253  
 granulocyte colony stimulating factor, 1372  
 growth hormone releasing peptide release, 980  
 growth hormone releasing peptide, 553
- heme oxygenase inhibitor, targeted delivery, 715  
 hepatic uptake clearance, 434  
 heptakis(2,6-di-*O*-ethyl)- $\beta$ -cyclodextrin, NMR, 208  
 hexamethylmelamine, periodic bond chain, 1052  
 hexamethylmelamine, structural morphology, 1052  
 histoculture, head and neck tumors, 1493  
 HIV-1 reverse transcriptase inhibitor, 56  
 HMG-CoA reductase inhibitor, 1461  
 hog liver flavin-containing monooxygenase, 1097  
 human growth hormone, 1106  
 human immunodeficiency virus protease inhibitor, 562  
 human ovarian carcinoma, 1434  
 hydrocolloid matrix, 1066  
 hydrocortisone, dissolution modeling, 1308  
 hydrocortisone, micelle systems, 865  
 hydrolases A and B, 639  
 hydrotalcite, 998  
 hydroxypropyl methylcellulose, drug release, 1693  
 hygroscopic growth, aerosol particles, 1  
 hyperlipidemic, 1206
- imidazolidine derivatives, 913  
 immunoliposome, 507  
 immunosuppressant FK506, analysis, 1785  
 in vitro cell culture model, Caco-2, 1710  
 indomethacin, enterohepatic circulation, 750  
 indomethacin, prodrugs, 1191  
 indomethacin, suppository, 927  
 influenza virus antigens, 1243  
 inhaled drugs, 871  
 insulin dissociation, 243  
 insulin, intrauterine delivery, 828  
 insulin, nasal delivery, 682  
 insulin, proteolytic degradation, 1638  
 insulin, pulmonary delivery, 228  
 interferon- $\beta$ , pharmacokinetics, 567  
 interferon- $\gamma$ , polyacryl starch microparticles, 783  
 interleukin-2/bilayer interaction, 1715  
 intestinal absorption, anesthetic, 884  
 intracellular delivery, 1130  
 intrapulmonary delivery, 1548  
 intravaginal administration, relaxin, 223  
 iontophoresis, 697, 1315  
 iontophoresis, 1699  
 iontophoresis, reverse, 1751
- kappa agonist analgesic, 1083  
 ketoconazole, pharmacokinetics, 418
- L-alanine crystal growth mechanism, 1008  
 L-phenylalanine methyl ester, demethylation, 1174  
 lag time, pharmacokinetics, 1030

- lake dye bleeding, 1458  
Langmuir-type protein binding, 49  
latex films, 405  
lauric acid, solubility, 1533  
lecithin, micelles, 865  
*Leishmania donovani*, 783  
linear variable displacement transducer, 816  
lipid bilayer membranes, 1654  
lipophilic antitumor prodrugs, 507  
lipophilic drugs, 1115  
liposomal phospholipid bilayer, PAC, 252  
liposome partitioning system, 913  
liposomes, hepatic uptake, 606  
liposomes, methylprednisolone, 1402  
liposomes, stability, 1228  
liposomes, sterilization, 1591  
liquid crystal, 737  
losartan polymorphs, 900  
losartan polymorphs, thermal analysis, 1793  
losartan, solution calorimetry, 1793  
low-substituted hydroxypropylcellulose, 351
- macrophage colony stimulating factor, rhM-CSF, 933  
magaldrate, 998  
maltodextrins, 1389  
membrane diffusion, 732, 839  
mepridpine, 1346  
mesalamine, 1286  
Met-enkephalin, 660  
metered dose inhaler, single puff, 1381  
metered dose inhalers, crystal growth, 454  
methadone, plasma, urine, cerebrospinal fluid, 441  
methionine sulfoxide, 1572  
methyl nicotinate, phonophoresis, 1726  
methylprednisolone, 1402  
metoprolol, extended-release, 28  
micellar solubilization, 631  
miconazole, buccal bioadhesive, 853  
microcrystalline cellulose, 61  
microdialysis, bite sampling, 335  
microemulsion, drug delivery, 1153  
microheterogeneity, 1580  
moisture sorption, tablet cores, 1212  
molecular mobility, 791  
monoamine oxidase (MAO), 1187  
monoclonal antibody, 1580  
mucociliary transport, anionic polymers, 411  
mucus layer, HT29, 843  
multifraction absorption models, 757  
multiphase microspheres, 1219
- N-phosphonacetyl-L-aspartate (PALA), 1434  
nanocapsules, poly(DL-lactide), 750  
nanospheres, pH-sensitive, 1544  
naproxen, prodrugs, 1191  
nasal absorption, kappa agonist analgesic, 1083  
nasal delivery, 1378  
nasal delivery-animal model, 1378  
nasal drug delivery, bisphosphonate, 924  
nasal mucosa, ovine, 1301  
nasal transport, 553  
National Formulary identity test, 61  
neomycin-resistance, 573  
neopterin, 567  
neural computing, pharmacokinetics, 466  
neural network, 165  
neurocomputing backpropagation, 165  
neuroprotective agent, gabapentin, 276  
nitroglycerin, 1341  
nonlinear clearance, ketoconazole, 418  
nonlinearity, 289  
nonspecific analytical assay, 889  
nucleoside transport, 423  
nucleoside transport, 611
- oleic acid-enhanced  $\beta$ -estradiol transdermal absorption, 1745  
oligonucleotides, 1427  
oligonucleotides, 1696  
ondansetron, intestinal absorption, 1722  
ophthalmic administration, nanocapsules, 80  
ophthalmic drug delivery, 109  
opioids, 1200  
opsonins, 606  
optimization of drug release, 1693  
oral administration, MRT, 8  
oral extended-release dosage forms, 1800  
oral immunization, 1243  
oral solid dosage form, release, 313  
organic cation transport, 1169  
organic mononitrites, pharmacokinetics, 22
- p*-chloro-*m*-xylenol, isotopes, stability, 1466  
P-glycoprotein, 743  
pafenolol, absorption interaction, 879  
pafenolol, gastrointestinal absorption, 130  
pafenolol, intestinal absorption, 727  
pafenolol, pharmacokinetics, 727  
pancreatic lipase, 1181  
parathion, humidity, 152  
parathion, percutaneous absorption, 152  
parenteral fat emulsions, 535  
particle deposition, 871  
particle size, absorption, 264  
pellets, microcrystalline cellulose, 356  
penetration enhancer, 381, 1500  
pentagastrin-pretreated dog, 1157  
peptide carrier-mediated transport, 400  
peptide degradation, 95, 1572  
peptide drug delivery, 473  
peptide map, porcine growth hormone, 1471  
peptide reactivity, human serum, 1268  
peptide stability, drug development, 1268  
peptide, oral absorption, 1790  
peptides, intestinal absorption, 271  
peptides, metabolism, 271  
peptides, permeability, 1710  
percutaneous absorption, 1015  
percutaneous absorption, skin irritants, 1756  
percutaneous penetration, 1291  
perfused rat liver, 434  
permeability coefficient, Caco-2, dog, monkey, rabbit, 113  
Peyer's patch, 1228  
pH dependent dissolution, 1037  
pH, skin permeation, 986  
pH-sensitive polymers, 1544  
pharmaceutical analysis, precision, accuracy, 1420  
pharmacokinetics, pafenolol, 130  
pharmacophore development, 475  
phenobarbital, polymorphism, 577  
phenylephrine oxazolidine, stereochemistry, 1507  
phenylephrine oxazolidines, ocular bioavailability, 1627  
phenylephrine, 1627  
phenylmorphinan, conformation, 1200  
phonophoresis, methyl nicotinate, 1726  
phosphatidylserine liposomes, 549  
phospholipids, 774  
phosphoryloxyethyl carbamates, 1350  
physical aging, latex films, 405  
physicochemical stability, phenobarbital, 577  
physiological parameters, 1093  
pilocarpine, controlled delivery, 109  
piroxicam, topical penetration, 1326  
poly(DL-lactic acid) nanoparticles, drug loaded, 1732  
poly(DL-lactic acid), 542  
poly(DL-lactic-co-glycolic acid), 1219  
poly( $\epsilon$ -caprolactone), 386  
poly(glycolide-colactide)microspheres, 113  
poly(lactide-co-glycolide), 362  
poly(vinylpyrrolidone), 791

- polyanhydride microspheres, 487  
 polydisperse powders, dissolution rates, 1308  
 polymeric aqueous dispersion, 1732  
 polymeric micelles adriamycin, 895  
 polymeric micelles, drug delivery systems, 970  
 polymeric nanocapsules, metipranolol, 80  
 polymorphs, 900  
 porcine growth hormone, 954  
 porcine growth hormone, peptide map, 1471  
 porcine pancreatic elastase, 1478  
 prinomide tromethamine, pharmacokinetics, 49  
 procaterol, bioavailability, 603  
 procaterol, pharmacokinetics, 603  
 prodrug hydrolysis, 1181  
 prodrugs of peptides, 68  
 prodrugs, 1812  
 propranolol hydrochloride, enantiomers, 1648  
 propranolol, enantiomers, 294  
 propranolol, inflammation, 294  
 protein aggregation, 954  
 protein binding, 300  
 protein drug delivery, 473  
 protein drugs, rat kidney perfusion, 823  
 protein folding, 1812  
 protein loading, 457  
 protein-stabilizing effects, 1232  
 protein/bilayer interaction, 1715  
 proteolysis, hGM, 1106  
 pulmonary delivery, insulin, 228  
 pyridines, 732  
 quinoline derivative, 1587  
 quinolines, 839  
 r-huG-CSF, pulmonary absorption, 1604  
 Raman spectroscopy, stratum corneum, 1642  
 ranitidine HCL, 1688  
 ranitidine, 1027  
 ranitidine, intestinal absorption, 1722  
 rat kidney perfusion, protein drugs, 823  
 recombinant human granulocyte-CSF, 1372  
 recombinant human relaxin, 1563  
 relaxin oxidation, 1563  
 relaxin absorption, 834  
 relaxin, intravaginal administration, 223  
 relaxin, intravaginal, 834  
 remoxipride, modified release, 1020  
 remoxipride, suspension, 1020  
 renal drug targeting, 963  
 retrodialysis, 1411  
 reversible metabolism, 8, 1451  
 rhM-CSF degradation, 933  
*Saccharomyces boulardii*, 1615  
 saturable transport, 1548  
 Schiff bases of hydroxyaminoguanidines, 515  
 self-emulsifiable solid, 1071  
 semisolid formation TGF- $\alpha$ , 1238  
 site-specific drug delivery, transfollicular, 1738  
 skin irritation, 1736  
 skin permeability, risk assessment, 930  
 skin permeation, pH, 986  
 sodium acid pyrophosphate, 1027  
 sodium caprate, 857  
 sodium ion dependence, 423  
 solid state stability, 1389  
 solid-state diode laser, 328  
 solid-state nuclear magnetic resonance spectroscopy, 317  
 solid-state nuclear magnetic resonance, drugs, 197  
 solute-solvent interactions, 737  
 solution theory, 1262  
 steady-state bioavailability, 28  
 stereomeric 1,4:3,6-dianhydrohexitol mononitrates, 22  
 stereoselective interaction, organic cations, 1169  
 stereoselective release, propranolol HCL, 1648  
 structure-activity relationship, 918  
 styryl carbinol antifungal agent, 309  
 subcutaneous tissue, pharmacokinetic monitoring, 598  
 succinylated human serum albumin, 1611  
 sulfotransferases, 627  
 surelease, 810  
 sustained release dosage forms, 1683  
 sustained-release, matrix base, 351  
 swelling and dissolution kinetics, 980  
 tablet diluents, 1597  
 tablet strength, 88  
 tabletting characteristics, 1597  
 tacrine, 44  
 targeting of drugs, 636  
*Taxes brevifolia*, 521  
 taxol, 521  
 tensile strength, cast films, 810  
 tetragastrin, intestinal absorption, 1488  
 tetragastrin, lipophilic derivatives, 1488  
 theophylline, 1321  
 theophylline, bioavailability, 588  
 theophylline, controlled release, 1037  
 theophylline, sustained release, 588  
 thermal treatment, tablets, 542  
 thermosensitive liposomes, 1332  
 thiazolobenzimidazole, solubilization, 1136  
 thixotropic gels, 220  
 tight junction permeability, 991  
 tin mesoporphyrin, 715  
 tracheal epithelium, 991  
 transdermal delivery, 1500  
 transdermal delivery, peptide protein drugs, 697  
 transdermal drug delivery, 381, 1521  
 transdermal drug delivery, diamorphine, 583  
 transdermal, estradiol, 1745  
 transepidermal drug delivery, 1632  
 transforming growth factor- $\alpha$  (TGF- $\alpha$ ), 1238  
 transient steady state, 1090  
 TRH, intestinal absorption, 667  
 TRH, paracellular permeability, 674  
 triglyceride emulsions, 774  
 trospectomycin sulfate bulk drug, 75  
 tumors, head, neck, 1493  
 UDP-glucuronosyltransferases, 461  
 vaccine delivery system, tetanus, 945  
 valproate, aging, 1046  
 valproate, pharmacodynamics, 1046  
 valproic acid, CNS transport, 1765  
 valproic acid, microdialysis, 1765  
 vitamin C tablets, bioavailability, 239  
 vitamin C, disintegration, 239  
 water soluble drug delivery system, 391  
 water vapor absorption, 1262  
 Winkler Method, dissolved oxygen, 305  
 zero-order release, hydrocolloid matrix, 1066  
 zidovudine chemical delivery system, 1356  
 zidovudine, 1338